Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial.

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-05-05 DOI:10.1016/j.jacbts.2025.03.010

Efthymios Ziogos, Tarek Harb, Ines Valenta, Michael A Vavuranakis, Palmer L Foran, Marlene S Williams, Michael J Blaha, Allison G Hays, Steven R Jones, Thomas H Schindler, Steven P Schulman, Gary Gerstenblith, Thorsten M Leucker

引用次数: 0

Abstract

In a randomized trial with 55 participants from the Evolocumab in Acute Coronary Syndrome trials, patients with non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI received a single dose of evolocumab or placebo, with myocardial inflammation assessed via ¹⁸F-fluorodeoxyglucose positron emission tomography scans at baseline and at 30 days. Evolocumab significantly reduced inflammation (SUV_mean) compared with placebo. PCSK9 levels at 30 days correlated with SUV_mean, and higher SUV_mean was linked to increased end-systolic volume at 6 months. These findings suggest that early PCSK9 inhibition reduces post-MI myocardial inflammation and may influence cardiac remodeling in the months following the acute event.

查看原文本刊更多论文

院内PCSK9抑制对心肌梗死后心肌炎症的影响：一项随机临床试验

在一项随机试验中，55名受试者来自Evolocumab在急性冠状动脉综合征试验中，非st段抬高型心肌梗死（MI）或st段抬高型心肌梗死（MI）的患者接受单剂量Evolocumab或安慰剂，在基线和30天通过18f -氟脱氧葡萄糖正电子发射断层扫描评估心肌炎症。与安慰剂相比，Evolocumab显著减少炎症（SUVmean）。30天的PCSK9水平与SUVmean相关，而较高的SUVmean与6个月时收缩末期容积增加有关。这些发现表明，早期抑制PCSK9可减少心肌梗死后的心肌炎症，并可能影响急性心肌梗死后数月的心脏重构。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.